ALBT vs. GMDAQ, TCBP, FNCH, ELOX, WINT, TCON, KRBP, PALI, ACORQ, and FRTX
Should you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Gamida Cell (GMDAQ), TC Biopharm (TCBP), Finch Therapeutics Group (FNCH), Eloxx Pharmaceuticals (ELOX), Windtree Therapeutics (WINT), TRACON Pharmaceuticals (TCON), Kiromic BioPharma (KRBP), Palisade Bio (PALI), Acorda Therapeutics (ACORQ), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDAQ) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability, community ranking and media sentiment.
50.3% of Gamida Cell shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 6.7% of Gamida Cell shares are held by company insiders. Comparatively, 64.0% of Avalon GloboCare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Avalon GloboCare has lower revenue, but higher earnings than Gamida Cell. Avalon GloboCare is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Gamida Cell and Avalon GloboCare both received 0 outperform votes by MarketBeat users.
In the previous week, Avalon GloboCare had 6 more articles in the media than Gamida Cell. MarketBeat recorded 7 mentions for Avalon GloboCare and 1 mentions for Gamida Cell. Avalon GloboCare's average media sentiment score of 1.08 beat Gamida Cell's score of 0.57 indicating that Gamida Cell is being referred to more favorably in the media.
Gamida Cell has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Gamida Cell has a net margin of 0.00% compared to Gamida Cell's net margin of -1,304.14%.
Summary
Gamida Cell beats Avalon GloboCare on 7 of the 12 factors compared between the two stocks.
Get Avalon GloboCare News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalon GloboCare Competitors List
Related Companies and Tools
